Investor Presentation - First Six Months of 2021

8 Investor presentation First six months of 2021 Novo NordiskⓇ Biopharm sales grew by 7% driven by both North America Operations and International Operations DKK billion 12 10 8 Reported Biopharm sales Growth at CER 7% 11% 39% 30% 3% 2% 6 Rare blood disorders 4 2 Biopharm sales driven by global commercial execution Biopharm sales growth driven by: 12% growth in North America Operations 4% sales growth in International Operations Rare blood disorders sales increased by 11%, driven by: Uptake of launch products EsperoctⓇ and Refixia® Novo Eight® and NovoSevenⓇ Rare endocrine disorders sales increased by 2%, driven by: New indications and global roll-out of the next-generation device Novo Nordisk is the leading company in the global human growth disorder market with a value market share of ~36% compared to ~34% a year ago 0 Total1 Rare blood disorders² Haem. A Haem. B Novo- ! SevenⓇ Rare endocrine disorders³ 1 Total includes "Other Biopharm", which consists of primarily Vagifem® and Activelle®: 2 Comprises NovoSeven®, Novo Eight®, Esperoct®, Refixia® and NovoThirteenⓇ; 3 Primarily Norditropin®. Note: NovoThirteenⓇ is not shown for Rare blood disorders. Haem. A: Haemophilia A; Haem. B: Haemophilia B; Unless otherwise specified, sales growth is at constant exchange rates

View entire presentation